Global Antibody Drug Conjugates Market Analysis and Value Forecast Snapshot by E

Posted by Rashi Pande on December 11th, 2019

Antibody-Drug Conjugates are the chemical linker which connects cytotoxic agents to the antibody. This enables the ADC to target and bind to cell-surface proteins called antigens that can be found on cancer cells and release its cell-killing drugs only after it has been internalized by the cancer cell.

Global antibody drug conjugates market is expected to grow at a growing CAGR of 23.46 %in the forecast period of 2019-2026. Increase in strategic alliances between the pharmaceuticals companies and high demand of disease specific novel therapies are the key factors that fueling the market growth. Few of the major competitors currently working in the global antibody drug conjugates market are Alteogen, F. Hoffmann-La Roche Ltd, Astellas Pharma Inc, Seattle Genetics, Inc, ImmunoGen Inc, Pfizer Inc, AbbVie Inc, Takeda Pharmaceutical Company Limited, LegoChem Biosciences, Inc, Daiichi Sankyo Company, AstraZeneca, Eli Lilly and Company, CELGENE CORPORATION, Sutro Biopharma, Inc, Sanofi, INNATE PHARMA S.A, Progenics Pharmaceuticals, Inc, Sorrento Therapeutics, Inc, Synthon International Holding B.V. , Novartis AG and others

To uncover the general market conditions and tendencies, Antibody Drug Conjugates Market research report acts as a perfect source. This report helps in planning by providing precise and state-of-the-art information about the consumer’s demands, preferences, attitudes and their changing tastes about the specific product. The Antibody Drug Conjugates Market report is a window to the Pharmaceutical industry which explains what market definition, classifications, applications, engagements and market trends are. The numerical data of this report is mainly backed up by two statistical tools such as SWOT analysis and Porter’s Five Forces Analysis. The Antibody Drug Conjugates Market report plays key role in keeping hold of reputation of the firm and its products.

Market Drivers

• Ongoing clinical trial  conducted by many pharmaceuticals industries is propelling the growth of this market
• Increase in special designation from the regulatory authorities is boosting the market growth
• Major advancements in linker technology is likely to drive the market
• High demand of disease specific novel treatment can also act as a market driver
• The competitive scenario of market and strategic collaborations may boost the market position

Market Restraints

• Limited operating revenue opportunities for research and development of targeted therapies by many pharmaceuticals is acting as a challenging factor for the growth of this market
• Low healthcare budget in some developing countries is hamper the market growth
• Patent expiration of branded drugs and introduction of generics is also hinders the market growth

Segmentation: Global Antibody Drug Conjugates Market

By Mechanism of Action

• CD Antibodies
• HER Antibodies
• Others

By Technology

• Cleavable Linker
• Non-cleavable Linker

By Application

• Blood Cancer
• Breast Cancer
• Ovarian Cancer
• Lung Cancer
• Others

By Drugs

• Adcetris
• Kadcyla
• Besponsa
• Others

By Route of Administration

• Oral
• Injectable

By End Users

• Hospitals
• Specialty Clinics
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies

By Geography

• North America
  • U.S.
  • Canada
  • Mexico
• South America
  • Brazil
  • Argentina
  • Peru
  • Rest of South America
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Turkey
  • Belgium
  • Netherlands
  • Hungary
  • Lithuania
  • Austria
  • Ireland
  • Norway
  • Poland
  • Switzerland
  • Rest of Europe
• Asia-Pacific
  • Japan
  • China
  • South Korea
  • India
  • Australia
  • Singapore
  • Thailand
  • Malaysia
  • Indonesia
  • Philippines
  • Vietnam
  • Rest of Asia Pacific
• Middle East & Africa
  • South Africa
  • UAE
  • Kuwait
  • Israel
  • Egypt
  • Rest of Middle East & Africa

Want Full Report? Enquire Here @ https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-antibody-drug-conjugates-market

Key Developments in the Market:

• In March 2019, LegoChem Biosciences, Inc entered into research collaboration with Takeda Pharmaceutical Company Limited to develop an antibody-drug conjugate for treatment of immune-oncology disorders. This collaboration can expand their market share and emphasizing their superiority in the oncology business.
• In March 2018, Daiichi Sankyo Company, Limited received SAKIGAKE Designation from the Japan Ministry of Health, Labour and Welfare (MHLW) for DS-8201, HER2-targeting antibody drug conjugate (ADC) for the treatment of HER2-positive advanced gastric or gastroesophageal junction cancer. With this designation, accelerates review timelines and enhances the interaction with the regulatory authority which can bring this potentially disease-modifying drug for patients as quickly as possible.

Competitive Analysis:

Global antibody drug conjugates market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares global antibody drug conjugates market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.